Peptide Biologix
Compound index
The atlas

GHRP-2 Technical Specification Sheet

GH / GHRH Axis · MW 817.97 g/mol · Pralmorelin, KP-102 · Synthetic hexapeptide GHS-R1a agonist and growth hormone secretagogue; GHRP-2 remains listed in Category 2 (503B) on FDA’s compounding bulk drug substances page current as of April 22, 2026.

Botanical plate of a young plant with its branching root system exposed
Plate 10GHRP-2
Primary Amino Acid Sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂

Molecular Properties

Parameter Value
Chemical Name Growth Hormone Releasing Peptide-2 / Pralmorelin
Amino Acid Sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂
Molecular Formula C₄₅H₅₅N₉O₆
Molecular Weight 817.97 g/mol
CAS Number 158861-67-7
Sequence Length 6 amino acids (synthetic hexapeptide with D-amino acids)
Receptor Target Growth Hormone Secretagogue Receptor 1a (GHS-R1a) / Ghrelin receptor

Physical Properties

Property Specification
Appearance White to off-white lyophilized powder
Solubility Soluble in water or aqueous buffer at ≥1 mg/mL; pH 5.5-7.5
pH (1% solution) 5.5 - 7.5
Hygroscopicity Low to moderate; standard desiccated storage
Solution Stability Stable at 4°C for 10-14 days; D-amino acids enhance stability

Analytical Specifications

Test Specification
HPLC Purity ≥98.0%
Mass Spectrometry Confirmed [M+H]⁺ = 817.97 ± 0.5 Da
Peptide Content ≥95% (by amino acid analysis)
Endotoxin Level <1.0 EU/mg
Acetate Content ≤5%
TFA Content ≤0.1%
Water Content ≤6% (Karl Fischer)

Storage Parameters

Condition Specification
Lyophilized Storage -20°C, desiccated
Lyophilized Shelf Life 24-36 months when stored properly
Reconstituted Storage 2-8°C for up to 14 days; -20°C for up to 3 months
Analytical Stock Preparation Dissolve in sterile water or aqueous buffer with gentle vortexing for 30 seconds
Freeze-Thaw Cycles Tolerates up to 5 cycles; D-amino acids provide stability
Light Sensitivity Low; standard laboratory storage acceptable

In Vitro & Preclinical Model Concentrations

Literature summary of published study doses, routes, and schedules.
Experimental Model Published Concentration / Regimen Exposure Schedule Administration Context
In Vitro Pituitary Cell Assays 10-1000 nM Acute stimulation (30 min to 2 hours) Culture media
Small Animal Models (Rodent) 50-500 μg/kg 1-3x daily SC or IV in rodent models
GH Secretion Studies (Rodent) 100-300 μg/kg Single bolus or repeated over 7-28 days SC in rodent models
Appetite/Ghrelin Research (Rodent) 200-600 μg/kg 30-60 min before measurements SC or IP in rodent models

Note: Concentrations and animal regimens summarized above are for research reference only. GHRP-2 is intended for laboratory research and mimics ghrelin action at the GHS-R1a receptor.

Key Research Studies

Literature summary of published study doses, routes, and schedules.
Year Study Focus Key Findings
1995 Discovery and characterization of GHS-R GHRP-2 identified as potent synthetic ligand for orphan GPCR (later named GHS-R1a); demonstrated EC₅₀ of 0.1-1 nM for GH release; 10-100x more potent than GHRH in vitro
1999 Synergy with GHRH Combined GHRP-2 + GHRH administration produced synergistic GH response (5-10x vs either alone); demonstrated distinct receptor mechanisms and complementary signaling pathways
2006 Appetite stimulation and orexigenic effects GHRP-2 (300 μg/kg SC) increased food intake by 40-60% within 2 hours in animal models; activated NPY/AgRP neurons in arcuate nucleus; effects blocked by GHS-R1a antagonists
2012 Cardioprotective and anti-inflammatory effects GHRP-2 treatment (200 μg/kg twice daily) reduced infarct size by 30-40% in cardiac ischemia models; decreased inflammatory markers (IL-6, TNF-α); GHS-R1a-dependent and independent mechanisms identified

Mechanism of Action

Biological Pathway Description
GHS-R1a Activation Binds ghrelin receptor (GHS-R1a), Gq-coupled GPCR; high affinity (Kd ~0.5-5 nM); expressed in pituitary, hypothalamus, heart, adipose
GH Secretion Activates pituitary somatotrophs → PLC/PKC pathway → Ca²⁺ mobilization → GH release; peak GH at 15-30 minutes post-stimulus
Hypothalamic Effects Stimulates arcuate NPY/AgRP neurons → orexigenic response; modulates GHRH neuron activity; amplifies endogenous GH pulses
Peripheral Actions Cardioprotection via GHS-R1a-dependent and independent mechanisms; anti-inflammatory effects; modulation of adipocyte function
Half-Life 20-30 minutes (IV/SC); D-amino acids provide resistance to peptidases vs natural peptides

Comparative Analysis: GHRP Family

Compound MW (Da) GH Potency Appetite Effect Cortisol/Prolactin
GHRP-2 817.97 High (EC₅₀ ~0.1-1 nM) Strong (+40-60%) Moderate increase
GHRP-6 872.44 High (EC₅₀ ~0.2-2 nM) Very strong (+60-100%) Moderate increase
Hexarelin 887.04 Very high (EC₅₀ ~0.05-0.5 nM) Moderate (+20-40%) Strong increase
Ipamorelin 711.85 Moderate (EC₅₀ ~1-10 nM) Minimal No increase (selective)

Quality Control Parameters

Test Method Acceptance Criteria
Appearance (visual) White to off-white powder; no aggregation
Chiral Purity D-amino acids at positions 1, 2, 5 confirmed; >98% correct stereochemistry
RP-HPLC (purity) Main peak ≥98.0%; no single impurity >0.5%
ESI-MS (identity) [M+H]⁺ = 817.97 ± 0.5 Da confirmed
Biological Activity ≥85% potency vs reference in GH release assay

Structure-Activity Relationship

Position Amino Acid Structural Role
1 D-Ala N-terminal stability; prevents aminopeptidase degradation
2 D-2-Nal (D-2-naphthylalanine) Critical for receptor binding; aromatic interaction with GHS-R1a
3 L-Ala Conformational spacer
4 L-Trp Essential for activity; indole ring interactions
5 D-Phe Receptor selectivity; D-configuration critical
6 L-Lys-NH₂ C-terminal; positive charge; amidation essential

Reported Biological Effects

Effect Category Observed Changes Timeframe
GH Secretion Peak GH increase 5-20x baseline; occurs 15-30 min post-stimulus; duration 1-2 hours Acute (minutes to hours)
IGF-1 Levels Increased 30-50% with repeated administration in animal models; cumulative effect over 1-2 weeks 7-14 days
Appetite Increased food intake 40-60% in rodent models; peak effect 1-3 hours post-stimulus Acute (1-4 hours)
Body Composition (Preclinical) Increased lean mass 2-5%; modest fat reduction in chronic animal studies 4-8 weeks

Regulatory & Compounding Status (April 2026)

On FDA’s page on bulk drug substances used in compounding, current as of April 22, 2026, GHRP-2 is listed in Category 2 under 503B (bulk drug substances that raise significant safety risks in compounding). Pralmorelin hydrochloride has been used in Japan as a single-dose diagnostic agent for growth hormone deficiency, but GHRP-2 is not approved by the U.S. FDA for human therapeutic use. This monograph is intended strictly for laboratory research.

External References

  1. Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-45. https://pubmed.ncbi.nlm.nih.gov/6143887/
  2. Smith RG, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621-45. https://academic.oup.com/edrv/article/18/5/621/2548680
  3. National Center for Biotechnology Information. PubChem Compound Summary for GHRP-2. https://pubchem.ncbi.nlm.nih.gov/compound/GHRP-2